Clinical Trials
74
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (74 trials with phase data)• Click on a phase to view related trials
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: SHR-A2009 ; AumolertinibDrug: Aumolertinib
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 576
- Registration Number
- NCT07183189
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Drug: SHR-8068，adebelizumab and platinum-based chemotherapyDrug: tislelizumab, and platinum-based chemotherapy
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT07170995
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
- Conditions
- Advanced Malignancy
- Interventions
- Drug: SHR-7782 Injection
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07123129
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil InjectionDrug: Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT07118527
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Zhongshan Hospital，Fudan University, Shanghai, Shanghai Municipality, China
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
- Conditions
- PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
- Interventions
- Drug: SHR-A1811 for InjectionDrug: SHR-1316 Injection
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT07111832
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital，Fudan University, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next